

Prescribing Clinical Network

Policy Statement	Perindopril <u>Arginine</u>
Policy Number	PCN 304-2018
Date of Issue	January - 2018
Review Date:	January - 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations:	
<p>The Prescribing Clinical Network does not recommend the use of perindopril <u>arginine</u></p> <p>Perindopril <u>arginine</u> will be considered BLACK on the traffic light system and prescribers should:</p> <ul style="list-style-type: none"> • NOT initiate perindopril arginine in any new patients AND • Switch any patients taking perindopril <u>arginine</u> to perindopril erbumine in line with NHS England guidance. 	
Key Considerations:	
<ul style="list-style-type: none"> • NHS England guidance 'Items which should not routinely be prescribe in primary care: Guidance for CCGs' - https://www.england.nhs.uk/wp-content/uploads/2017/11/items-which-should-not-be-routinely-prescribed-in-pc-ccg-guidance.pdf • Perindopril arginine is significantly more expensive than perindopril erbumine • PrescQIPP review of the topic found there was no clinical advantage of the arginine salt https://www.prescqipp.info/-perindopril-arginine/send/89-perindopril-arginine/1009-bulletin-59-perindopril-arginine • NICE CG127: Hypertension in adults: diagnosis and management recommends that prescribing costs are minimised. 	
Date taken to Prescribing Clinical Network	10 th January 2018
Agreed by PCN members	22 nd January 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG